Frazier Life Sciences Management’s Soleno Therapeutics SLNO Stock Holding History

Frazier Life Sciences Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-499,159	Closed	-$35.7M	–	55
2025 Q1	$35.7M	Sell	499,159 -200,000	-29%	-$9.74M	1.63%	15
2024 Q4	$31.4M	Sell	699,159 -176,508	-20%	-$9.15M	1.3%	19
2024 Q3	$44.2M	Hold	875,667	–	–	1.77%	18
2024 Q2	$35.7M	Hold	875,667	–	–	1.67%	19
2024 Q1	$37.5M	Buy	875,667 +410,730	+88%	+$18.6M	1.58%	19
2023 Q4	$18.7M	Hold	464,937	–	–	1%	29
2023 Q3	$13.7M	Buy	+464,937	New	+$2.81M	0.91%	28

Other funds holding SLNO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Frazier Life Sciences Management's SLNO Position: Q2 2025 in Review

Frazier Life Sciences Management sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 499,159 shares — an estimated $35.7M sold.

Frazier Life Sciences Management first reported a position in SLNO in Q3 2023 and held it in 7 quarters. The position peaked at $44.2M in Q3 2024. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

Frazier Life Sciences Management reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 499,159 Soleno Therapeutics shares in Q2 2025, an estimated $35.7M.
Frazier Life Sciences Management first reported a position in Soleno Therapeutics in Q3 2023 and held it in 7 quarters.
Frazier Life Sciences Management's Soleno Therapeutics position peaked at $44.2M in Q3 2024.
233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Frazier Life Sciences Management's 13F filing for Q2 2025, filed 14 Aug 2025.